Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Hagerty Fourth Quarter 2025 Earnings Call - New Markel Fronting Arrangement Creates 2026 GAAP Noise Despite Strong Underlying Growth
Hagerty closed 2025 with strong top-line and profit momentum, driven by a record 371,000 new members, double-digit premium growth and efficiency gains that lifted full-year net income 91% to $149 mill...
- Record new members: Hagerty added 371,000 new members in 2025, fueling recurring premium growth and ecosystem adoption.
- Strong 2025 financials: Full-year revenue up 17%, net income up 91% to $149 million, and operating cash flow up 24% to $219 million.
- Written premium momentum: Written premiums grew 14% for full year 2025 and 19% in Q4, driven by new business and State Farm ramp.
- +12 more takeaways
Eos Energy Enterprises Q4 2025 Earnings Call - Missed Guidance, Indensity and Automation Roadmap Aim to Deliver 2026 Ramp
Eos closed 2025 with headline wins and an uncomfortable caveat. Revenue exploded to $114.2 million, up more than 7x year over year, and Q4 posted a record $58 million, yet the company missed its guida...
- Company missed its guidance for the quarter, CEO Joe Mastrangelo takes responsibility, but demand remains intact.
- Record revenue growth: Q4 revenue $58 million, FY 2025 revenue $114.2 million, roughly 7x year-over-year growth.
- Backlog and bookings: $701 million backlog at year end, bookings of ~1.1 GWh across eight customers and nine projects in Q4, and $240 million in new orders during the quarter.
- +13 more takeaways
Evolv Technology Fourth Quarter 2025 Earnings Call - Direct fulfillment fuels revenue and RPO growth, but trims near-term gross margins
Evolv closed 2025 with clear top-line momentum and a refreshed business mix. Q4 revenue was $38.5 million, up 32% year-over-year, and full-year revenue reached $145.9 million, up 40%. ARR finished at ...
- Q4 2025 revenue $38.5 million, up 32% year-over-year; full-year revenue $145.9 million, up 40% year-over-year.
- ARR at year-end 2025 was $120.5 million, up 21% year-over-year, with management expecting ARR growth to accelerate in 2026.
- RPO increased to $293.4 million, a 13% year-over-year gain, reflecting Gen2 upgrades and multiyear subscription terms.
- +15 more takeaways
OptimizeRx Q4 2025 Earnings Call - Strong profitability and cash generation, but MFN-led contract softness trims 2026 revenue guide
OptimizeRx closed fiscal 2025 with strong profitability, margin expansion, and a meaningful cash build, but management is dialing back top-line expectations for 2026 amid contract timing shifts and ca...
- Q4 2025 revenue was $32.2 million, with adjusted EBITDA of $12.0 million.
- Full-year 2025 revenue totaled $109.4 million and adjusted EBITDA was $24.3 million, with adjusted EBITDA margins above 20% for the year.
- OptimizeRx generated roughly $18.7 million in operating cash flow in 2025 and ended the year with $23.4 million in cash and short-term investments, up from $13.4 million a year earlier.
- +12 more takeaways
Yalla Group Limited Q4 2025 Earnings Call - Mid-core and SLG launches set to drive H2 growth as MENA focus deepens
Yalla closed 2025 with healthy top-line and margin expansion while signaling a deliberate shift into higher‑value gaming categories concentrated on the MENA market. Q4 revenue was $83.9 million and fu...
- Q4 2025 revenue was $83.9 million; full year 2025 revenue reached $341.9 million.
- Full year net income grew double digits to $148.1 million; Q4 net income was $34.5 million, up 6.2% year‑over‑year.
- Monthly active users reached 44.8 million in Q4, an 8.2% increase year‑over‑year.
- +12 more takeaways
INOVIO Pharmaceuticals Q4 2025 Earnings Call - INO-3107 BLA Accepted but FDA Flags Accelerated Approval Eligibility; PDUFA Oct 30, 2026
INOVIO’s call was all about one thing, and rightly so. The company’s BLA for INO-3107 in recurrent respiratory papillomatosis was accepted for FDA review under the Accelerated Approval Program, with a...
- FDA accepted INOVIO’s BLA for INO-3107 under the Accelerated Approval Program, with a standard 10-month review and a PDUFA target date of October 30, 2026.
- During the 60-day filing review the FDA raised a preliminary concern that INOVIO had not provided adequate information to justify Accelerated Approval eligibility, a first for this filing.
- INOVIO submitted an Assessment Aid in February to bolster its Accelerated Approval rationale and is awaiting the FDA to schedule a meeting, while the BLA remains under active review and INOVIO continues to respond to routine information requests.
- +12 more takeaways
Figure Technology Solutions Q4 2025 Earnings Call - Figure Connect exceeds 50% of marketplace volume, accelerating capital-light model
Figure used Q4 to show the business moving from proof to scale. Connect now handles more than half of consumer loan marketplace volume and Figure says that transition is already making the model mater...
- Figure Connect crossed a major milestone in Q4, accounting for 54% of consumer loan marketplace volume, a meaningful push toward a capital-light model.
- Consumer loan marketplace volume was $2.7 billion in Q4, up 131% year-over-year, with 307 partners active on the platform.
- Adjusted net revenue reached $158 million, a 106% year-over-year increase, driven by higher marketplace volume and asset-based servicing and interest income.
- +12 more takeaways
Syndax Pharmaceuticals Fourth Quarter 2025 Earnings Call - Revuforj and Niktimvo Drive Rapid Commercial Momentum
Syndax closed 2025 as a commercial company in earnest, delivering $172.4 million in revenue led by two newly launched drugs. Revuforj generated $124.8 million in its first full year with a sharp Q4 ac...
- Total 2025 revenue was $172.4 million, driven by $124.8 million in Revuforj net revenue and Syndax’s $42.4 million collaboration share of Niktimvo sales.
- Revuforj Q4 net revenue was $44.2 million, up 38% quarter-over-quarter, with prescriptions up ~35% q/q and roughly 1,050 patients treated commercially since launch.
- Label expansion into relapsed/refractory NPM1-mutated AML (approved end of October 2025) meaningfully enlarged the Revuforj addressable population; early indicators show NPM1 accounted for ~30% of new starts in Q4 and management expects that to grow.
- +11 more takeaways
Cryoport Q4 2025 Earnings Call - Commercial CGT Momentum and Path to Positive Adjusted EBITDA in H2 2026
Cryoport closed 2025 with revenue from continuing operations of $176.2 million, beating prior guidance and driven by accelerating commercial cell and gene therapy activity. Commercial revenue grew 29%...
- Continuing-operations revenue for full year 2025 was $176.2 million, above the high end of prior guidance.
- Commercial cell and gene therapy revenue increased 29% year-over-year and totaled a record $33.4 million for 2025, representing about 20% of total revenue.
- Clinical trial revenue grew 14% year-over-year to $47.1 million, and Cryoport concluded 2025 supporting a company-stated record 760 clinical trials and 20 commercial therapies worldwide.
- +12 more takeaways
California Resources Corporation Fourth Quarter 2025 Earnings Call - Record results, deeper inventory and CCS moving to commissioning
California Resources closed 2025 with production growth for the third straight year, record financials and a heavier return of cash to shareholders, all while oil prices were down 14% year over year. ...
- Third consecutive year of production growth in 2025, with net production up about 25% year over year to ~138,000 BOE/d for the full year.
- Record financial performance: full-year adjusted EBITDAX nearly $1.25 billion, free cash flow of $543 million; Q4 adjusted EBITDAX $251 million and Q4 free cash flow $115 million (including 14 days from Berry).
- Massive inventory disclosure: nearly 1.2 billion BOE of 2P reserves, which management says supports roughly 23 years of development at current production levels; 1P reserves grew 350% and have an implied SEC-value of about $9 billion.
- +12 more takeaways